SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, today presented the results of a preclinical study that further supports the Company’s understanding of an aspect of the mechanism of action of Contrave™, one of its two late-stage obesity drug candidates. The findings showed: The combination of bupropion and naltrexone resulted in a 94% reduction of food intake in obese mice, greater than either drug alone; The drugs act in a part of the brain where food reward pathways are located; The combination directly increased firing of neurons associated with reduction in food intake and satiety.
